Nataša Grubiša

Initiatives to Reduce Nonprescription Sales and Dispensing of Antibiotics: Findings and Implications

Vanda Marković‐Peković, Nataša Grubiša, Johanita R. Burger et al. · Journal of Research in Pharmacy Practice · 2017 · 103 citations · Full text

Pharmacy, Community Pharmacy, Pharmacy Practice +13

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Evelien Moorkens, Brian Godman, Isabelle Huys et al. · Frontiers in Pharmacology · 2021 · 68 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacology +17

Self‐medication with antibiotics in the Republic of Srpska community pharmacies: pharmacy staff behavior

Vanda Marković‐Peković, Nataša Grubiša · Pharmacoepidemiology and Drug Safety · 2012 · 45 citations

Pharmacy, Community Pharmacy, Pharmacy Practice +12

Pricing of oral generic cancer medicines in 25 European countries; findings and implications

Brian Godman, Andrew Hill, Steven Simoens et al. · Generics and Biosimilars Initiative Journal · 2019 · 45 citations · Full text

Pharmacy, Oncology, Pharmaceutical Policy +17

Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study

Una Glamočlija, Biljana Tubić, Martin Kondža et al. · Croatian Medical Journal · 2018 · 14 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +16